E-Mail
A key driver of patients well-being and clinical trials for Parkinson s disease (PD) is the course the disease takes over time. However, nearly all that is known about the genetics of PD is related to susceptibility a person s risk for developing the disease in the future. A new study by investigators from Brigham and Women s Hospital published in
Nature Genetics uncovers the genetic architecture of progression and prognosis, identifying five genetic locations (loci) associated with progression. The team also developed the first risk score for predicting progression of PD over time to dementia (PDD), a major determinant of quality of life.
BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease 8th April 2021 (Last Updated April 8th, 2021 18:15)
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
The trial plans to enrol ten patients in the US and Canada. Credit: National Institute on Aging, National Institutes of Health.
Share Article
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
A progressive neurodegenerative disorder, PD is caused by damage to nerve cell in the brain, causing lower dopamine levels. The deterioration of motor and non-motor symptoms is because of dopamine-producing neuron loss.
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson s Disease
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson s Disease (PD). This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson s disease. We re excited to initiate this study with our expert collaborators at University Health Network in Toronto as we believe this trial could shift the treatment paradigm for PD patients in Canada and around the world, states Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock. Our therapy is intended to replace the midbrain dopaminergic neurons lost in the